SMTL ID : 5x2a.1 (1 other biounit)

Crystal structure of EGFR 696-1022 T790M/V948R in complex with SKLB(3)

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.85 Å

Oligo State

homo-dimer

Ligands

1 x CL: CHLORIDE ION(Non-functional Binders)

CL.1: 6 residues within 4Å: Chain A: M.102, P.103, F.104, V.154, K.155, M.311 Ligand excluded by PLIP

5 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)

EDO.2: 5 residues within 4Å: Chain A: R.241, R.257, W.260, M.261 Ligands: EDO.3 2 PLIP interactions: 2 interactions with chain A Hydrogen bonds: A:R.241, A:R.257 EDO.3: 4 residues within 4Å: Chain A: M.254, R.257, K.258 Ligands: EDO.2 No protein-ligand interaction detected (PLIP) EDO.4: 3 residues within 4Å: Chain A: D.251, K.279, Y.287 3 PLIP interactions: 3 interactions with chain A Hydrogen bonds: A:E.276, A:Y.287, A:Y.287 EDO.5: 3 residues within 4Å: Chain A: Q.244, T.249, I.250 3 PLIP interactions: 3 interactions with chain A Hydrogen bonds: A:Q.244, A:Q.244, A:I.250 EDO.6: 5 residues within 4Å: Chain A: Y.110, N.117, Y.122, H.297 Chain B: E.45 5 PLIP interactions: 3 interactions with chain A, 2 interactions with chain B Hydrogen bonds: A:N.117 Water bridges: A:Y.122, A:H.297, B:E.45, B:E.45

1 x 7XO: N2-[4-(4-methylpiperazin-1-yl)phenyl]-N8-phenyl-9-propan-2-yl-purine-2,8-diamine(Non-covalent)

7XO.7: 16 residues within 4Å: Chain A: L.27, V.35, A.52, K.54, M.99, Q.100, L.101, M.102, P.103, G.105, E.113, L.153, T.163, D.164 Ligands: ANP.8, MG.9 12 PLIP interactions: 12 interactions with chain A Hydrophobic interactions: A:L.27, A:V.35, A:V.35, A:K.54, A:K.54, A:L.153 Hydrogen bonds: A:M.102, A:M.102, A:G.105 Water bridges: A:T.163, A:T.163 Salt bridges: A:E.113

2 x ANP: PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER(Non-covalent)

ANP.8: 14 residues within 4Å: Chain A: G.28, S.29, G.30, A.31, F.32, G.33, V.35, K.54, D.146, R.150, N.151, D.164 Ligands: 7XO.7, MG.9 9 PLIP interactions: 9 interactions with chain A Hydrogen bonds: A:A.31, A:K.54, A:D.146, A:D.146, A:R.150, A:N.151 Water bridges: A:F.32, A:G.33 Salt bridges: A:K.54 ANP.11: 21 residues within 4Å: Chain B: L.27, G.28, S.29, G.30, A.31, G.33, V.35, A.52, K.54, M.99, Q.100, L.101, M.102, C.106, D.146, R.150, N.151, L.153, D.164 Ligands: MG.10, MG.12 14 PLIP interactions: 14 interactions with chain B Hydrogen bonds: B:A.31, B:Q.100, B:M.102, B:C.106, B:D.146, B:D.146, B:R.150, B:N.151, B:D.164 Water bridges: B:F.32, B:F.32, B:Q.100, B:D.109 Salt bridges: B:K.54

3 x MG: MAGNESIUM ION(Non-covalent)

MG.9: 6 residues within 4Å: Chain A: R.150, N.151, T.163, D.164 Ligands: 7XO.7, ANP.8 No protein-ligand interaction detected (PLIP) MG.10: 5 residues within 4Å: Chain B: K.54, D.164, L.167 Ligands: ANP.11, MG.12 No protein-ligand interaction detected (PLIP) MG.12: 4 residues within 4Å: Chain B: N.151, D.164 Ligands: MG.10, ANP.11 2 PLIP interactions: 2 interactions with chain B Metal complexes: B:D.164, B:D.164

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Zhu, S.J. et al., Structural insights into drug development strategy targeting EGFR T790M/C797S. Oncotarget (2018)

Release Date

2018-02-07

Peptides

Epidermal growth factor receptor: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
D

Epidermal growth factor receptor

Related Entries With Identical Sequence